Literature DB >> 25578483

HIV/AIDS and rheumatoid arthritis.

Bernardo M Cunha1, Licia Maria H Mota2, Gecilmara S Pileggi3, Izabella P Safe4, Marcus V G Lacerda5.   

Abstract

The acquired immunodeficiency syndrome (AIDS) is an infectious disease caused by the human immunodeficiency virus (HIV). It was first recognized in the United States in 1981, and the HIV/AIDS epidemic has since spread to affect all countries. The interface of HIV/AIDS with opportunistic infectious diseases is well characterized, but further research is required into the concurrence of other chronic diseases. The objective of this review was to identify possible interferences of HIV infection in the diagnosis and management of rheumatoid arthritis (RA). A review of the available evidence was conducted using the GRADE approach. Overall, the quality of evidence was low. Our main conclusions were: (1) the occurrence of rheumatoid-like arthritis in patients with HIV/AIDS is quite rare; therefore, it is not recommended that HIV infection be considered routinely as a differential diagnosis in this condition (C2); (2) HIV infection may lead to rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody positivity, but usually at low titers (C1); (3) RA might cause false-positive HIV serology and ELISA seems to be a more specific test for HIV in patients with RA (C2); (4) RA and AIDS may coexist, even in cases of severe immunosuppression (C1); (5) RA emergence may seldom occur during or after immune reconstitution (C1); and (6) there is insufficient safety data to recommend use of specific disease-modifying antirheumatic drugs (DMARDs) in RA patients with HIV/AIDS. Therefore, these drugs should be used cautiously (C1).
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AIDS; Disease-modifying antirheumatic drugs; HIV; Rheumatoid arthritis; Rheumatoid factor

Mesh:

Substances:

Year:  2015        PMID: 25578483     DOI: 10.1016/j.autrev.2015.01.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  9 in total

Review 1.  Targeting the programmed cell death-1 pathway in rheumatoid arthritis.

Authors:  Sabina Sandigursky; Gregg J Silverman; Adam Mor
Journal:  Autoimmun Rev       Date:  2017-05-29       Impact factor: 9.754

Review 2.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

Review 3.  Rheumatoid arthritis in patients with HIV: management challenges.

Authors:  Matthew B Carroll; Joshua H Fields; Philip G Clerc
Journal:  Open Access Rheumatol       Date:  2016-04-29

4.  Rheumatoid polyarthritis suspected in an HIV patient with scleritis, peripheral ulcerative keratitis, and anterior uveitis.

Authors:  Christelle Domngang Noche; Madeleine Singwé-Ngandeu; Assumpta Lucienne Bella
Journal:  Int Med Case Rep J       Date:  2016-02-04

5.  Autoimmune diseases and HIV infection: A cross-sectional study.

Authors:  Emilie Virot; Antoine Duclos; Leopold Adelaide; Patrick Miailhes; Arnaud Hot; Tristan Ferry; Pascal Seve
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  Case report: Safety and efficacy of adalimumab in treating difficult-to-treat rheumatoid arthritis in a human immunodeficiency virus-positive patient, one year follow-up.

Authors:  Jing-Wen Chen; Guo-Shu Deng; Wen-Shuang Zhang; Ming-Ying Zhang; Tong Guan; Qiang Xu
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

7.  Matrine Exerts a Strong Anti-Arthritic Effect on Type II Collagen-Induced Arthritis in Rats by Inhibiting Inflammatory Responses.

Authors:  Jiang Pu; Fan-Fu Fang; Xiu-Qing Li; Zhi-Heng Shu; Yi-Ping Jiang; Ting Han; Wei Peng; Cheng-Jian Zheng
Journal:  Int J Mol Sci       Date:  2016-08-26       Impact factor: 5.923

Review 8.  Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in thepre- and post-HAART eras.

Authors:  Luis E Vega; Luis R Espinoza
Journal:  Clin Rheumatol       Date:  2020-04-15       Impact factor: 2.980

9.  Bone Deleterious Effects of Different NRTIs in Treatment-naïve HIV Patients After 12 and 48 Weeks of Treatment.

Authors:  Patricia Atencio; Francisco Miguel Conesa-Buendía; Alfonso Cabello-Ubeda; Patricia Llamas-Granda; Ramón Pérez-Tanoira; Laura Prieto-Pérez; Beatriz Álvarez Álvarez; Irene Carrillo Acosta; Rosa Arboiro-Pinel; Manuel Díaz-Curiel; Raquel Largo; Gabriel Herrero-Beaumont; Miguel Górgolas; Aránzazu Mediero
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.341

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.